1342836-14-9

Upstream product

• 1158763-48-4 5-(3-fluorophenyl)pyridine-2-carbaldehyde 
• 2136-75-6 (triphenylphosphoranylidene)acetaldehyde 
• 768-35-4 3-fluorophenylboronic acid 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 

Downstream Products

• 1342886-19-4 4-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]vinyl}-2-methyloctahydropyrrolo[3,4-a]-indolizine-1,3-dione 
• 1342886-26-3 (S)-4-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]vinyl}-7-hydroxy-2-methylhexahydro-pyrrolo[3,4-a]pyrrolizine-1,3-dione 
• 1342886-25-2 tert-butyl 8-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]vinyl}-2-methyl-1,3-dioxodecahydro-2,5,7a-triazacyclopenta[a]indene-5-carboxylate 

Relevant academic research and scientific papers

Pyridylvinylpyrazoloquinolines as PAR1 inhibitors

The disclosure relates to compounds of formula I: wherein the groups R1, R2, R3, R4, R5 and X are as defined in the disclosure, having antithrombotic activity, which in particular inhibits the protease-activated receptor 1 (PAR1). The disclosure further relates to methods for producing the same and to the use thereof as a pharmaceutical product.

TRICYCLIC PYRIDYL-VINYL PYRROLES AS PAR1 INHIBITORS

This disclosure relates to compounds of formula I: wherein R1, R2, R3, R4, X and Y have the meanings denoted in the disclosure. The compounds of formula I have antithrombotic activity and in particular inhibit the protease-activated receptor 1 (PAR1). The disclosure further relates to a method for producing the compound of formula I and to the use thereof as a pharmaceutical product.